Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 102 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Facial Neoplasms Clear all
Completed Phase 3 Interventional

Clinical Trial of New Elastomer for Maxillofacial Prosthetics

NCT00123097
View directory record Official record
Conditions
Facial Neoplasms, Head and Neck Neoplasms, Head Injuries, Penetrating, Birth Injuries
Interventions
Chlorinated polyethylene elastomer
Combination Product
Lead sponsor
University of Louisville
Other
Eligibility
21 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 7, 2017 · Synced Oct 21, 2026, 10:03 AM EDT
Completed Phase 1 Interventional

Ingenol Mebutate 0.015% Gel in the Treatment of Actinic Keratoses (AK) on the Face and Scalp

NCT01836367
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Ingenol Mebutate 0.015%
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 31, 2013 · Synced Oct 21, 2026, 10:03 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Voices: Messages of Wisdom and Hope in the Face of Illness

NCT07381179
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 21, 2026, 10:03 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Assess Recurrence of Actinic Keratosis in Participants Treated With Methyl Aminolevulinate Hydrochloride Cream or Vehicle Cream Who Achieved Complete Response to Treated Lesions in Earlier Study

NCT04269395
View directory record Official record
Conditions
Keratosis, Actinic
Interventions
MAL Cream, Vehicle cream
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
52
States / cities
Fort Smith, Arkansas • Encinitas, California • Fountain Valley, California + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 21, 2026, 10:03 AM EDT
Active, not recruiting Phase 1 Interventional

Assessing Impact of Early Physiotherapy on Lymphatic Dysfunction in Head and Neck Cancer Survivorship

NCT05937269
View directory record Official record
Conditions
Lymphedema of Face, Head and Neck Cancer
Interventions
Near-infrared fluorescence lymphatic imaging, advanced pneumatic compression therapy
Combination Product · Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 21, 2026, 10:03 AM EDT
Completed Not applicable Interventional Results available

Menadione Topical Lotion in Treating Skin Discomfort and Psychological Distress in Patients With Cancer Receiving Panitumumab, Erlotinib Hydrochloride, or Cetuximab

NCT01393821
View directory record Official record
Conditions
Dermatologic Complications, Malignant Neoplasm, Pain
Interventions
menadione topical lotion, placebo, questionnaire administration, management of therapy complications
Drug · Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
2
States / cities
Phoenix, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 21, 2026, 10:03 AM EDT
Completed Not applicable Interventional

Comparing Numbing Techniques in Mohs Micrographic Surgery

NCT07222241
View directory record Official record
Conditions
Skin Cancer Face, Skin Cancer Scalp
Interventions
Nerve Block, Placebo Nerve Block
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 21, 2026, 10:03 AM EDT
Completed Phase 1 Interventional

Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors

NCT00413322
View directory record Official record
Conditions
Tumor
Interventions
belinostat, 5-Fluorouracil (5-FU)
Drug
Lead sponsor
Valerio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
3
States / cities
Scottsdale, Arizona • Omaha, Nebraska • Portsmouth, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Oct 21, 2026, 10:03 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% in Adult Participants With Actinic Keratosis

NCT05279131
View directory record Official record
Conditions
Keratosis, Actinic
Interventions
Tirbanibulin ointment 1%
Drug
Lead sponsor
Almirall, S.A.
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
7
States / cities
Hot Springs, Arkansas • Encinitas, California • Sweetwater, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Oct 21, 2026, 10:03 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

PatientSpot Formerly Known as ArthritisPower

NCT03840928
View directory record Official record
Conditions
Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity
Interventions
Not listed
Lead sponsor
Global Healthy Living Foundation
Other
Eligibility
19 Years and older
Enrollment
40,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Upper Nyack, New York
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Oct 21, 2026, 10:03 AM EDT
Completed Phase 3 Interventional Results available

A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp

NCT01541553
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Cryotherapy, Vehicle, Ingenol metabute
Procedure · Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
35
States / cities
Fremont, California • Oceanside, California • San Diego, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 21, 2026, 10:03 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome

NCT03697109
View directory record Official record
Conditions
Cushing Syndrome
Interventions
Relacorilant, Placebo
Drug · Other
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
32
States / cities
Phoenix, Arizona • Los Angeles, California • Torrance, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 21, 2026, 10:03 AM EDT
Completed No phase listed Observational

Machine Learning to Analyze Facial Imaging, Voice and Spoken Language for the Capture and Classification of Cancer/Tumor Pain

NCT04442425
View directory record Official record
Conditions
Cancer, Neoplasms, Solid Tumors
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 120 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 21, 2026, 10:03 AM EDT
Completed Not applicable Interventional

Effectiveness of Narrow Margins in Patients With Low-Risk Basal Cell Carcinoma Undergoing Surgery

NCT02579551
View directory record Official record
Conditions
Skin Basal Cell Carcinoma
Interventions
Therapeutic Conventional Surgery
Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
Not listed
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 21, 2026, 10:03 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Increasing Strengths, Safety and Efficacy of Two Formulas of LEO 43204 on the Face or the Chest in Patients With Actinic Keratosis

NCT01922050
View directory record Official record
Conditions
Actinic Keratosis
Interventions
LEO 43204 Formulation 1, LEO 43204 Formulation 2, LEO 43204 Formulation 1 Dose X, LEO 43204 Formulation 1 Dose Y, LEO 43204 Formulation 2 Dose XX, LEO 43204 Formulation 2 Dose YY, Placebo Formulation 1, Placebo Formulation 2
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
13
States / cities
Phoenix, Arizona • Lomita, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 21, 2026, 10:03 AM EDT
Completed Phase 3 Interventional Results available

An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome

NCT00936741
View directory record Official record
Conditions
Cushing's Syndrome
Interventions
mifepristone
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
15
States / cities
Birmingham, Alabama • Escondido, California • Stanford, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2014 · Synced Oct 21, 2026, 10:03 AM EDT
Terminated Not applicable Interventional

Enhancing Facial Nerve Function With Omega-3 After Resection of Vestibular Schwannoma

NCT05116878
View directory record Official record
Conditions
Vestibular Schwannoma
Interventions
Omega-3, Placebo
Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 8, 2023 · Synced Oct 21, 2026, 10:03 AM EDT
Completed Not applicable Interventional

Post-parotidectomy Facial Paresis: Intraoperative and Postoperative Factors

NCT02527226
View directory record Official record
Conditions
Parotid Neoplasms, Facial Paralysis
Interventions
Facial exercises
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 16, 2016 · Synced Oct 21, 2026, 10:03 AM EDT
Terminated Phase 2 Interventional Results available

Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex

NCT03363763
View directory record Official record
Conditions
Angiofibroma of Face, Tuberous Sclerosis
Interventions
Sirolimus 0.2%, Sirolimus 0.4%, Placebo ointment
Drug
Lead sponsor
Aucta Pharmaceuticals, Inc
Industry
Eligibility
2 Years to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
7
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Oct 21, 2026, 10:03 AM EDT
Completed Phase 4 Interventional Results available

Bacteriostatic Saline as a Local Anesthetic in Minor Eyelid Procedures

NCT05294640
View directory record Official record
Conditions
Eyelid Tumor, Eyelid Bump, Eyelid Deformity, Eyelid Abscess, Eyelid Boil, Eyelid Papilloma, Anesthesia, Local, Ophthalmology
Interventions
0.9% Bacteriostatic Local Anesthetic Injection, 1% Lidocaine with 1:100,000 epinephrine Local Anesthetic Injection, Eyelid Lesion Removal
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 110 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Oct 21, 2026, 10:03 AM EDT
Withdrawn Phase 3 Interventional

Phase 3 Study of Levulan With New Blue Light for AK on the Face or Scalp

NCT03024060
View directory record Official record
Conditions
Actinic Keratosis
Interventions
ALA, Vehicle, IBL 20 mW, IBL 10 mW
Drug · Device
Lead sponsor
DUSA Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
7
States / cities
San Diego, California • Arlington Heights, Illinois • Carmel, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Oct 21, 2026, 10:03 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Diclofenac Sodium Gel, 3% to Solaraze® Gel, 3% in the Treatment of Actinic Keratosis on the Face or Bald Scalp

NCT02611804
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Diclofenac sodium, Placebo
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
492 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
30
States / cities
Mesa, Arizona • Tucson, Arizona • Fremont, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 5, 2017 · Synced Oct 21, 2026, 10:03 AM EDT
Completed Phase 2 Interventional Results available

A Multicenter Study to Evaluate the Safety and Efficacy of PEP005 Topical Gel When Used to Treat Actinic Keratoses on the Head (Face or Scalp)

NCT00700063
View directory record Official record
Conditions
Actinic Keratosis
Interventions
PEP005 Topical Gel, Vehicle gel
Drug
Lead sponsor
Peplin
Industry
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
25
States / cities
Hot Springs, Arizona • Little Rock, Arkansas • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Oct 21, 2026, 10:03 AM EDT
Completed Phase 3 Interventional Results available

A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on Actinic Keratosis on Face or Scalp (AK004)

NCT03285490
View directory record Official record
Conditions
Actinic Keratosis
Interventions
KX2-391 Ointment 1%, Placebo
Drug
Lead sponsor
Almirall, S.A.
Industry
Eligibility
18 Years and older
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
30
States / cities
Phoenix, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2021 · Synced Oct 21, 2026, 10:03 AM EDT